Novo Nordisk slammed with an RTF as the FDA raises CMC issues
Novo Nordisk’s blockbuster diabetes drug Ozempic (semaglutide) has already made the Danish drugmaker billions of dollars, and the company is aiming to capitalize on that success by expanding into higher doses and other indications like obesity and NASH. But late Monday the FDA told Novo: